Analysts have been eager to weigh in on the Healthcare sector with new ratings on Definitive Healthcare Corp (DH – Research Report), RegenXBio (RGNX – Research Report) and Henry Schein (HSIC – Research Report).
Henry Schein (HSIC)
Piper Sandler analyst Jason Bednar assigned a Buy rating to Henry Schein on January 17 and set a price target of $78.00. The company’s shares closed last Monday at $74.61.
According to TipRanks.com, Bednar has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on Henry Schein is a Hold with an average price target of $74.22.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on DH:
- Definitive Healthcare downgraded to Hold from Buy at Needham
- Definitive Healthcare price target lowered to $11 from $12 at Stifel
- Definitive Healthcare price target lowered to $9 from $10 at Canaccord
- Definitive Healthcare sees FY24 revenue up 5%-7%, consensus $273.5M
- Definitive Healthcare Announces CEO Transition
